Breast cancer is becoming less deadly for younger women: US study
Overall, the breast cancer death rate in this age group fell from 9.70 per 100,000 women in 2010 to 1.47/100,000 in 2020. The decline was sharper after 2016, likely due to advancements in treatment options, greater uptake of precision medicine, and expanded access to care and screening in women ages 40-49, study leader Adetunji Toriola of the Washington University School of Medicine in St. Louis said in a statement.
While breast cancer mortality declined in every racial and ethnic group, non-Hispanic Black women had the highest rate in both 2010 (16.56/100,000) and 2020 (3.41/100,000). Non-Hispanic white women had the lowest rates in 2010 (9.18/100,000) and 2020 (1.16/100,000). 'We have made tremendous advances in reducing mortality from breast cancer in young women but there are still opportunities for improvements, especially in relation to eliminating disparities,' Toriola said. 'We must continue to perform impactful research to ensure a further reduction in breast cancer mortality, including research into understanding the tumour biology and molecular mechanisms driving carcinogenesis and treatment response in younger women.'
GLP-1 DRUGS MAY CURB ATRIAL FIBRILLATION GLP-1 drugs that are used to treat diabetes and have become wildly popular for weight loss, may also be useful for controlling the common heart rhythm disorder atrial fibrillation, researchers reported at the Heart Rhythm 2025 meeting in San Diego. Researchers looked at more than 2,500 patients with type 2 diabetes, atrial fibrillation and obesity at 170 US Veterans Affairs medical centres. Those who were receiving a GLP-1 drug experienced a 13% reduction in major AF-related events during a median follow-up of three years, compared to patients receiving other medications for their diabetes.
AF-related events included hospitalisations for the disorder, need for electroshock therapy to reset the heart rhythm, and ablation procedures to heat heart tissue in order to create scars that interrupt the electrical signals causing the arrhythmia. Researchers did not identify the drugs being taken but common examples of GLP-1 medicines for diabetes include Novo Nordisk's Ozempic, Rybelsus and Victoza, and Eli Lilly's Mounjaro and Trulicity.
Because patients were taking low doses of GLP-1 drugs, rather than higher doses used for weight loss, the results suggest the arrhythmia benefits are independent of any weight-loss benefit, the researchers noted. The study was not designed to prove the GLP-1 drugs caused the reduction in AF events. But study leader Dr Varun Sundaram of the Louis Stokes Cleveland VA Medical Center and Case Western Reserve University said, 'Given the growing obesity epidemic and the rising prevalence of atrial fibrillation,' it lays the foundation for a new approach to treating AF if larger trials confirm the potential benefits.
— Reuters
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Observer
16-07-2025
- Observer
Pharmacists must be Omanis
The Ministry of Health (MOH) has issued a circular 167/2025 calling for mandatory Omanization in pharmacies located within commercial complexes and hospital facilities. The directive specifically states that licenses for non-Omani pharmacists and their assistants will no longer be renewed. The decision has been widely welcomed, particularly by Omani pharmacy graduates who have long voiced concerns about the lack of employment opportunities in private pharmacies, which have been largely dominated by expatriate professionals for years. For many pharmacy graduates in the Sultanate, the circular marks a long-awaited turning point. Saeed al Amri, a recent graduate with a pharmacy degree from a local university, expressed his optimism, saying, 'My classmates and I have been waiting for a decision like this since graduation. Unfortunately, the private sector has been heavily reliant on expat pharmacists. Now, we feel a real opportunity is emerging for us.' Abdulla al Hosani, an Omani pharmacist currently working in a private healthcare facility, echoed the sentiment, stating: 'This is not just about replacing expats. It's about investing in local talent. We are well-trained and more than capable of leading the pharmacy sector forward.' Recent statistics from the Ministry of Higher Education reveal a growing number of pharmacy graduates from both local and international institutions. Yet employment rates among these graduates remain modest, particularly within private institutions, where cost considerations often lead to the hiring of lower-paid foreign workers. While the decision has been largely applauded, stakeholders agree that implementing Omanization requires parallel efforts to ensure that Omani pharmacists are fully equipped to take on their roles in the private sector. Kholood Al-Balushi, a trainee pharmacist, believes that readiness is key: 'As graduates, we must rise to the challenge. The job market is competitive, and we need to continuously improve our skills. Securing opportunities should be matched with personal development.' Some private pharmacy owners have also highlighted the importance of additional support measures, such as financial incentives or training programs to ensure a smooth transition. The Ministry of Health emphasized that the circular is part of a broader national vision under Oman Vision 2040 to create sustainable employment opportunities for is a carefully considered policy decision based on employment data and field studies. The ministry is committed to working closely with private healthcare providers to ensure that this transition is implemented effectively without compromising the quality of healthcare services. Experts believe this directive will contribute to a broader shift in private sector employment dynamics. With more Omanis entering the pharmacy field, patient communication and trust may improve due to shared language, cultural understanding, and stronger community bonds. Moreover, the decision may also encourage higher education institutions to enhance their pharmacy programs by aligning them more closely with the needs of the local job market. It is expected that government-led initiatives such as training subsidies, internship placements, and employer incentives will play a key role in supporting the Omanization process. Ultimately, the Omanization of the pharmacy profession signals a decisive step toward workforce sustainability in the healthcare sector. It not only offers a renewed sense of hope for hundreds of job-seeking graduates but also reaffirms the nation's long-term commitment to building a self-reliant healthcare system.
Muscat Daily
15-07-2025
- Muscat Daily
Pharmacist jobs in hospitals and commercial centres Omanised
By OUR CORRESPONDENT Muscat – Ministry of Health (MoH) has issued a directive mandating Omanisation of pharmacy jobs in commercial complexes and hospital-affiliated in-house pharmacies. A circular (No 167/2025) dated July 13, issued by the Drug Safety Centre under MoH, instructed that professional licences of non-Omani pharmacists and assistant pharmacists in these establishments will not be renewed. The directive takes immediate effect. Signed by Ibrahim Nasser al Rashdi, Director General of Drug Safety Centre, the circular forms part of broader national efforts to enhance employment opportunities for qualified Omani professionals in the pharmaceutical field. 'All concerned entities are urged to take the necessary steps to implement this directive in a timely manner,' the circular said. The circular has been sent to all pharmacies operating in commercial complexes and those affiliated with hospitals. The decision follows the Health Sector Employment Governance Committee's discussions in January with Majlis A'Shura's Youth and Human Resources Committee on key initiatives aimed at advancing employment of Omanis in the health sector, focusing on complete Omanisation of the pharmacy profession in the private sector.
Muscat Daily
15-07-2025
- Muscat Daily
Oman implements Omanisation policy in all commercial and hospital pharmacies
By OUR CORRESPONDENT Muscat – In a decisive move to boost national workforce development, the Ministry of Health's Drug Safety Center has issued a directive mandating Omanisation in all pharmacies operating within commercial complexes and internal hospital facilities. According to Circular No. 167/2025, dated 13 July 2025, all such pharmacies are now required to initiate Omanisation of their pharmaceutical workforce, in line with national employment strategies. The circular clearly states that effective immediately, the renewal of professional licenses for non-Omani pharmacists and assistant pharmacists in these establishments will no longer be permitted. Institutions have been urged to take the necessary steps to comply with this directive promptly to avoid any disruption to operations. The Ministry asked for full cooperation of all stakeholders in implementing this decision.
